Dhanuka Agritech Ltd Share Price Today

Dhanuka Agritech Ltd. Share Price

Overview

Dhanuka Agritech Ltd. share price is currently ₹972.19, down by - ₹0.80 (0.08%) from its previous closing price of ₹972.99. The share price has declined -2.82% over the past month and declined -38.45% over the past year. The stock's 52-week low and high are ₹882.20 and ₹1,595.07, respectively. Dhanuka Agritech Ltd. has a market capitalisation of ₹ 4,510.00 Cr. The share price was last updated on 11 Sep 2026, 03:29 PM IST.

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 100% at ₹2/Share	17-Jul-2026	17-Jul-2026
DividendsFinal Dividend of 100% at ₹2/Share	18-Jul-2025	18-Jul-2025

Actions

Ex-Date

Record-Date

DividendsFinal Dividend of 100% at ₹2/Share

17-Jul-2026

DividendsFinal Dividend of 100% at ₹2/Share

18-Jul-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
HDFC Mid Cap Fund - Regular Plan - Growth	10.29 Lac	10.29 Lac no change
ICICI Prudential Rural Opportunities Fund - Regular Plan - Growth	2.69 Lac	2.69 Lac no change
ICICI Prudential ESG Exclusionary Strategy Fund - Growth	89.59 k	91.17 k (1.77%)
JM Value Fund - Regular Plan - Growth	21.49 k	18.93 k (11.93%)
ICICI Prudential Conservative Hybrid Fund - Regular Plan - Growth	-	14.33 k (100%)

Mutual Fund Holder

Jul 26

Shares held

Aug 26

Shares held

HDFC Mid Cap Fund - Regular Plan - Growth

10.29 Lac

no change

ICICI Prudential Rural Opportunities Fund - Regular Plan - Growth

2.69 Lac

no change

ICICI Prudential ESG Exclusionary Strategy Fund - Growth

89.59 k

91.17 k

(1.77%)

JM Value Fund - Regular Plan - Growth

21.49 k

18.93 k

(11.93%)

ICICI Prudential Conservative Hybrid Fund - Regular Plan - Growth

14.33 k

(100%)

AALGO BREATHS I SEBI RA

8 Jul • 11:50 AM · SEBI-Registered Analyst

Orchid Pharma Limited Latest Updates

ORCHPHARMA

$178 Million Exblifep Licensing Deal in Russia On July 8, 2026, Orchid Pharma executed an exclusive licensing agreement with Russian pharmaceutical major Pharmasyntez JSC for its patented hospital antibiotic Exblifep. Under the deal, Pharmasyntez holds exclusive registration and marketing rights across Russia, while Orchid retains sole manufacturing and supply mandates. Pending Russian health ministry clearance, the partnership is projected to deliver cumulative revenues of $178 million over a 10-year horizon. Final NCLT Clearance for Dhanuka Laboratories Merger In June 2026, the National Company Law Tribunal (NCLT) issued a formal order sanctioning the amalgamation of promoter entity Dhanuka Laboratories Limited into Orchid Pharma Limited. Backdated to April 1, 2024, the structural merger consolidates product portfolios and API research assets, with management targeting combined annual revenues of ₹1,400–1,500 crore and EBITDA of ₹200–250 crore. FY26 Financial Summary For the fourth quarter ended March 31, 2026 (Q4 FY26), consolidated total income grew 15.1% quarter-on-quarter to ₹244.95 crore, while net profit (PAT) recovered to ₹23.78 crore. On a full-year basis, operating EBITDA margins faced mild headwinds due to elevated raw material prices across core cephalosporin bulk drug supply chains. SEBI Compliance Window In strict compliance with SEBI LODR and Insider Trading regulations, the company executed the formal closure of its internal trading window for all designated insider groups and connected persons on June 30, 2026. The trading restriction remains fully active pending the formal board adoption and presentation of the upcoming Q1 FY27 financial results.

Prameela Balakkala

13 Jun • 3:29 PM · SEBI-Registered Analyst

Orchid Pharma–Dhanuka Merger Creates ₹1,500 Cr Pharma Giant

ORCHPHARMA

Key Highlights Merger Approval: NCLT clears merger of Dhanuka Laboratories with Orchid Pharma. Revenue Potential: Combined entity expected to generate ₹1,400–1,500 crore revenue. EBITDA Outlook: EBITDA projected at ₹200–250 crore. Synergies: Operational efficiencies, cost savings, and stronger market presence. 📊 Financial Snapshot (Post-Merger Estimates) Metric Value Implication Revenue ₹1,400–1,500 Cr Strong topline growth. EBITDA ₹200–250 Cr Margin expansion potential. EBITDA Margin ~15–17% Healthy profitability. Debt Position Moderate Manageable leverage post-merger. ROCE ~12–14% Improved capital efficiency. ROE ~10–12% Stronger shareholder returns. ⚡ Growth Drivers Integrated operations → cost savings and efficiency. Expanded product portfolio → stronger domestic & export presence. Synergies in R&D and manufacturing. Enhanced scale → better bargaining power and market positioning. ⚠️ Risks Integration challenges between Orchid and Dhanuka. Regulatory hurdles in pharma approvals. Competitive pressures from larger peers (Sun Pharma, Dr. Reddy’s, Cipla). The merger positions Orchid Pharma as a mid-sized integrated pharma player with stronger fundamentals, improved margins, and enhanced market presence.

Chahat Aggrawal

2 Jun • 5:02 PM · SEBI-Registered Analyst

Dhanuka Agritech Announces ₹70 Cr Share Buyback

💰

DHANUKA

has announced a share buyback of 5,00,000 equity shares at ₹1,400 per share, aggregating to ₹70 crore. The buyback offer opens on June 4, 2026, providing an opportunity for eligible shareholders to participate.

Kumar Satyam

27 May • 9:37 PM · SEBI-Registered Analyst

Upcoming Buyback Record Dates

Key Dates to Track • 29 May 2026 – Cybertech Systems and Software • 29 May 2026 – Zydus Lifesciences • 29 May 2026 – Dhanuka Agritech • 05 June 2026 – Wipro Why Record Dates Matter To participate in a buyback, investors generally need to hold shares before the ex-date linked to the record date. Learning Outcome Buyback record dates are important corporate action events because they determine shareholder eligibility for participation in the offer.

WIPRO

Naveen Kumar

26 May • 10:22 AM · SEBI-Registered Analyst

BHARATRAS

good result is expected

harat Rasayan is a specialty agrochemical company (technical-grade pesticides). Q3 FY26 revenue Rs 287 Cr, up 9.2% YoY, with net profit Rs 40 Cr (up 44% QoQ vs Q2's Rs 28 Cr). EBITDA margin improved to 17.25% in Q3 vs 15% in Q2, signalling margin recovery trend. 9M FY26 revenue Rs 934 Cr and profit Rs 104 Cr, showing overall improvement. Key driver: global agrochemical de-stocking cycle (2023-25) now ending with restocking beginning. Peers: PI Industries reported strong Q4 with export growth; Dhanuka Agritech reported better margins; Rallis India showed recovery; Bayer CropScience (parent: Bayer AG) improved Q1 2026 globally. India rabi crop season (Jan-Mar) is key demand period for Bharat Rasayan. Board meeting May 26, 2026 to approve FY26 audited results. Promoter confidence visible (stable holding). With 9M FY26 PAT at Rs 104 Cr, Q4 required only Rs 40-50 Cr to hit FY26 targets. Margins improving YoY and industry cycle turning. Expect Q4 FY26 revenue Rs 300-320 Cr, PAT Rs 40-50 Cr, EBITDA margin 16-18%.

Kumar Satyam

17 May • 6:25 PM · SEBI-Registered Analyst

Upcoming Board Meetings for Potential Buybacks

Key Dates to Watch • 17 May 2026 – Balmer Lawrie and Company • 19 May 2026 – Zydus Lifesciences • 19 May 2026 – Dhanuka Agritech • 20 May 2026 – TeamLease Services Why It Matters Buybacks are often viewed positively as they can indicate: • Strong cash position • Confidence in business outlook • Shareholder-friendly capital allocation Learning Outcome Board meeting announcements related to buybacks are important corporate events because they can impact sentiment, earnings per share, and liquidity.

Dhanuka Agritech Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Dhanuka Agritech Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Dhanuka Agritech Ltd.?

What is the market cap of Dhanuka Agritech Ltd.?

Should I buy Dhanuka Agritech Ltd. stock now?

What is the 52 week high and low of Dhanuka Agritech Ltd.?

Is the Dhanuka Agritech Ltd. stock good to buy?

Is Dhanuka Agritech Ltd. a good buy for the long term?

Is Dhanuka Agritech Ltd. overvalued or undervalued?

What is the PE and PB ratio of Dhanuka Agritech Ltd.?